A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Chan, SL; Cheng, PNM; Liu, AM; Chan, LL; Li, L; Chu, CM; Chong, CCN; Lau, YM; Yeo, W; Ng, KKC; Yu, SCH; Mok, TSK; Chan, AWH

Chan, SL (corresponding author), State Key Lab Translat Oncol, Hong Kong, Peoples R China.; Chan, SL (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Hong Kong, Peoples R China.

INVESTIGATIONAL NEW DRUGS, 2021; 39 (5): 1375

Abstract

Background: Pegylated recombinant human arginase (PEG-BCT-100) is an arginine depleting drug. Preclinical studies showed that HCC is reliant on exogen......

Full Text Link